SMAD7 is a novel independent predictor of survival in patients with cutaneous melanoma

M. Kaczorowski , Przemysław Biecek , Piotr Donizy , Malgorzata Pieniazek , Rafal Matkowski , Agnieszka Halon


Overexpression of SMAD7-a hallmark inhibitor of transforming growth factor β (TGFβ) signaling-has been documented and related with adverse prognosis in a number of epithelial malignancies, suggesting that it may be responsible for resistance to TGFβ-induced growth arrest of cancer cells. The involvement of SMAD7 in development and progression of malignant melanoma is unclear, and its expression has not been characterized so far at the protein level in clinical melanoma tissue samples. We evaluated SMAD7 expression in 205 skin melanoma primary tumors by immunohistochemistry and correlated the findings with clinicopathological profiles of patients. Melanocytic SMAD7 was evidenced in 204 cases, and the expression pattern was predominantly nuclear. High expression of SMAD7 was positively associated with several features of tumor aggressiveness, for example, presence of ulceration (P < 0.001), higher tumor thickness (P < 0.001), and mitotic rate (P < 0.001), but not presence of regional or distant metastases. Moreover, high SMAD7 expression independently predicted unfavorable outcome: melanoma-specific survival (hazard ratio = 3.16, P < 0.001) and recurrence-free survival (hazard ratio = 2.88, P < 0.001). Taken together, our results underline the importance of TGFβ signaling in cancer and define SMAD7 as a marker of aggressive tumor behavior and adverse clinical outcomes in melanoma patients.
Author M. Kaczorowski
M. Kaczorowski,,
, Przemysław Biecek (FMIS / DCSDCAM)
Przemysław Biecek,,
- Department of CAD/CAM Systems Design and Computer-Aided Medicine
, Piotr Donizy
Piotr Donizy,,
, Malgorzata Pieniazek
Malgorzata Pieniazek,,
, Rafal Matkowski
Rafal Matkowski,,
, Agnieszka Halon
Agnieszka Halon,,
Journal seriesTranslational Research, ISSN 1931-5244, (N/A 140 pkt)
Issue year2019
Publication size in sheets0.5
Keywords in EnglishIHC = immunohistochemistry; IRS = immunoreactive score; MSS = melanoma-specific survival; RFS = recurrence-free survival; SLNB = sentinel lymph node biopsy; TGFβR = transforming growth factor β receptor; TGFβ = transforming growth factor β; TILs = tumor infiltrating lymphocytes
ASJC Classification2704 Biochemistry, medical; 2739 Public Health, Environmental and Occupational Health; 2700 General Medicine
Languageen angielski
Score (nominal)140
Score sourcejournalList
ScoreMinisterial score = 140.0, 31-12-2019, ArticleFromJournal
Publication indicators WoS Citations = 3; Scopus SNIP (Source Normalised Impact per Paper): 2017 = 1.213; WoS Impact Factor: 2018 = 4.915 (2) - 2018=4.516 (5)
Citation count*
Share Share

Get link to the record

* presented citation count is obtained through Internet information analysis and it is close to the number calculated by the Publish or Perish system.
Are you sure?